Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million

Reuters03-09

<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million

Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&D expenses fell 58% to USD 19.52 million, while G&A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa (TA-ERT) in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260309462150) on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618664076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618664076","market":"fut","top_or_hot":-1,"title":"Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> FY 2025 R&amp;D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&amp;D expenses fell 58% to USD 19.52 million, while G&amp;A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa (TA-ERT) in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260309462150) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> FY 2025 R&amp;D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&amp;D expenses fell 58% to USD 19.52 million, while G&amp;A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa (TA-ERT) in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260309462150) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLcfkyWl:1","article_id":"2618664076","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618664076","pubTimestamp":1773054325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&D expenses fell 58% to USD 19.52 million, while G&A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa  in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRB":"Spruce Biosciences, Inc."},"translate_title":"Spruce Biosciences 2025财年研发费用下降58%至1952万美元，净亏损收窄27%至3897万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":0.9},"content_text":"Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million\n    \n\n        Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&D expenses fell 58% to USD 19.52 million, while G&A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa (TA-ERT) in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260309462150) on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618664076","isCrawlerRequest":true}